These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17980105)

  • 1. [Detection of CDX-2, CK7 and CK20 in primary and metastatic ovarian carcinoma].
    Yuan ZF; Shi HR; Sun HM; Li WC
    Zhonghua Bing Li Xue Za Zhi; 2007 Aug; 36(8):555-6. PubMed ID: 17980105
    [No Abstract]   [Full Text] [Related]  

  • 2. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
    Groisman GM; Meir A; Sabo E
    Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
    Shin JH; Bae JH; Lee A; Jung CK; Yim HW; Park JS; Lee KY
    Jpn J Clin Oncol; 2010 Mar; 40(3):208-13. PubMed ID: 19926591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.
    Vang R; Gown AM; Zhao C; Barry TS; Isacson C; Richardson MS; Ronnett BM
    Am J Surg Pathol; 2007 Jun; 31(6):854-69. PubMed ID: 17527072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of cytokeratin 7 and 20 in ovarian metastatic carcinomas].
    Dai L; Song Q; Li L; Zhong D; Hui Y
    Zhonghua Bing Li Xue Za Zhi; 2001 Apr; 30(2):114-7. PubMed ID: 11866966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic.
    Perez Montiel D; Arispe Angulo K; Cantú-de León D; Bornstein Quevedo L; Chanona Vilchis J; Herrera Montalvo L
    Ann Diagn Pathol; 2015 Aug; 19(4):249-52. PubMed ID: 26059401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms.
    Chan ES; Alexander J; Swanson PE; Jain D; Yeh MM
    Am J Surg Pathol; 2012 May; 36(5):737-43. PubMed ID: 22498824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma.
    Saad RS; Silverman JF; Khalifa MA; Rowsell C
    Appl Immunohistochem Mol Morphol; 2009 May; 17(3):196-201. PubMed ID: 19098678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant cytokeratin expression as a possible prognostic predictor in poorly differentiated colorectal carcinoma.
    Yamagishi H; Imai Y; Okamura T; Fukuda K; Ono Y; Ban S; Inoue T; Ueda Y
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1815-22. PubMed ID: 23808938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression pattern of CK7, CK20, CDX-2, and villin in intestinal-type sinonasal adenocarcinoma.
    Kennedy MT; Jordan RC; Berean KW; Perez-Ordoñez B
    J Clin Pathol; 2004 Sep; 57(9):932-7. PubMed ID: 15333652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signet ring cell carcinoma of the ampulla of Vater: demonstration of a pancreatobiliary origin.
    Gheza F; Cervi E; Pulcini G; Villanacci V; Giulini SM; Schiavo-Lena M; Ferrari AB; Bassotti G
    Pancreas; 2011 Jul; 40(5):791-3. PubMed ID: 21673543
    [No Abstract]   [Full Text] [Related]  

  • 12. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray.
    Kim MJ
    J Korean Med Sci; 2005 Aug; 20(4):643-8. PubMed ID: 16100458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary ovarian carcinoid tumors may express CDX-2: a potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary.
    Rabban JT; Lerwill MF; McCluggage WG; Grenert JP; Zaloudek CJ
    Int J Gynecol Pathol; 2009 Jan; 28(1):41-8. PubMed ID: 19047909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunohistochemical profile of colorectal and ovarian carcinomas--examination with cytokeratin 7, cytokeratin 20, beta catenin and cDX 2].
    Porjazova E; Zaprjanov Z; Batashki I; Markova D; Milchev N
    Akush Ginekol (Sofiia); 2009; 48(2):7-12. PubMed ID: 20198769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
    McCluggage WG; Shah R; Connolly LE; McBride HA
    Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of immunohistochemistry in discriminating primary from secondary extramammary Paget disease.
    Perrotto J; Abbott JJ; Ceilley RI; Ahmed I
    Am J Dermatopathol; 2010 Apr; 32(2):137-43. PubMed ID: 20051815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum: I. Cytokeratin profile in 42 cases.
    Terada T
    Int J Clin Exp Pathol; 2013; 6(4):703-10. PubMed ID: 23573317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status.
    Lugli A; Tzankov A; Zlobec I; Terracciano LM
    Mod Pathol; 2008 Nov; 21(11):1403-12. PubMed ID: 18587323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CD7, CD20 and CDX-2 in a secondary signet-ring cell tumor of the prostate: a case report.
    Cimino S; Russo GI; Favilla V; Fragala E; Collura Z; Zanghi A; Castelli T; Madonia M; Morgia G
    Int J Immunopathol Pharmacol; 2013; 26(1):269-72. PubMed ID: 23527733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of macrophage migration inhibitory factor, p53 and CD34 in ovarian carcinoma].
    He CZ; Xia XA; Wu YY; Pu H; Lü B; Mao YR; Zhang ZY; Gao WH
    Zhonghua Bing Li Xue Za Zhi; 2007 Apr; 36(4):261-2. PubMed ID: 17706119
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.